BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci 2013;104:473-80. [PMID: 23298313 DOI: 10.1111/cas.12098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Mazières J, Brugger W, Cappuzzo F, Middel P, Frosch A, Bara I, Klingelschmitt G, Klughammer B. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 2013;82:231-7. [PMID: 23972450 DOI: 10.1016/j.lungcan.2013.07.016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
2 García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol 2019;9:849. [PMID: 31616627 DOI: 10.3389/fonc.2019.00849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
3 Teerapakpinyo C, Wanthong P, Aumchaaumchaya M, Chankate P, Kaikeaw W, Tosakorn W, Shaungshoti S. Pyrosequencing analysis of KRAS codon 61 mutations in Thai patients with advanced colorectal cancer. Asian Biomedicine 2017;9:61-7. [DOI: 10.5372/1905-7415.0901.369] [Reference Citation Analysis]
4 Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open 2018;3:e000353. [PMID: 29765773 DOI: 10.1136/esmoopen-2018-000353] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]